R&G PharmaStudies Co. Ltd. A Net Assets
R&G PharmaStudies Co. Ltd. A net assets. Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) has net assets worth CN¥2.00 Billion CNY (≈ $293.23 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.40 Billion ≈ $351.41 Million USD) and total liabilities (CN¥397.56 Million ≈ $58.18 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 301333 net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.00 Billion |
| % of Total Assets | 83.45% |
| Annual Growth Rate | 41.15% |
| 5-Year Change | 351.27% |
| 10-Year Change | N/A |
| Growth Volatility | 92.6 |
Net Assets of R&G PharmaStudies Co. Ltd. A (2019–2025)
Net assets of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. This chart illustrates how R&G PharmaStudies Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See R&G PharmaStudies Co. Ltd. A net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for R&G PharmaStudies Co. Ltd. A (2019–2025)
The table below shows the annual net assets of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. For live market cap and overall valuation, see how much is R&G PharmaStudies Co. Ltd. A worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.98 Billion ≈ $289.11 Million |
+7.60% |
| 2024-12-31 | CN¥1.84 Billion ≈ $268.68 Million |
+4.64% |
| 2023-12-31 | CN¥1.75 Billion ≈ $256.76 Million |
+10.10% |
| 2022-12-31 | CN¥1.59 Billion ≈ $233.21 Million |
+264.02% |
| 2021-12-31 | CN¥437.81 Million ≈ $64.07 Million |
+29.92% |
| 2020-12-31 | CN¥336.98 Million ≈ $49.31 Million |
+34.93% |
| 2019-12-31 | CN¥249.74 Million ≈ $36.55 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to R&G PharmaStudies Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 378.5% over the analyzed period, indicating profitable operations and earnings retention.
R&G PharmaStudies Co. Ltd. A Net Assets Breakdown (December 2025)
R&G PharmaStudies Co. Ltd. A net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥801.09 Million | 40.70% |
| Other Components | CN¥1.17 Billion | 59.30% |
| Total Equity | CN¥1.97 Billion | 100.00% |
R&G PharmaStudies Co. Ltd. A Competitors by Market Cap
The table below lists competitors of R&G PharmaStudies Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangzhou Pearl River Piano Group Co Ltd
SHE:002678
|
$816.92 Million |
|
InMode Ltd
NASDAQ:INMD
|
$817.13 Million |
|
United Renewable Energy Co Ltd
TW:3576
|
$817.45 Million |
|
Huafa Industrial Co Ltd Zhuhai
SHG:600325
|
$817.53 Million |
|
Dharma Satya Nusantara Ptdsn
JK:DSNG
|
$816.76 Million |
|
AIC Inc
TWO:3693
|
$816.73 Million |
|
Alto Neuroscience, Inc.
NYSE:ANRO
|
$816.73 Million |
|
Zbit Semiconductor Inc. A
SHG:688416
|
$816.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in R&G PharmaStudies Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,832,516,706 to 1,968,177,184, a change of 135,660,478 (7.4%).
- Net income of 136,899,589 contributed positively to equity growth.
- Dividend payments of 11,781,500 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥136.90 Million | +6.96% |
| Dividends Paid | CN¥11.78 Million | -0.6% |
| Other Changes | CN¥10.54 Million | +0.54% |
| Total Change | CN¥- | 7.40% |
Book Value vs Market Value Analysis
This analysis compares R&G PharmaStudies Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.84x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.94x to 2.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥5.28 | CN¥57.80 | x |
| 2020-12-31 | CN¥4.48 | CN¥57.80 | x |
| 2021-12-31 | CN¥5.87 | CN¥57.80 | x |
| 2022-12-31 | CN¥16.54 | CN¥57.80 | x |
| 2023-12-31 | CN¥18.21 | CN¥57.80 | x |
| 2024-12-31 | CN¥18.97 | CN¥57.80 | x |
| 2025-12-31 | CN¥20.38 | CN¥57.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently R&G PharmaStudies Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.96%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.09%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.22x
- Recent ROE (6.96%) is below the historical average (16.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 34.76% | 19.42% | 0.95x | 1.88x | CN¥58.86 Million |
| 2020 | 25.97% | 17.31% | 0.90x | 1.66x | CN¥51.55 Million |
| 2021 | 23.49% | 16.31% | 0.90x | 1.60x | CN¥56.98 Million |
| 2022 | 7.15% | 17.79% | 0.34x | 1.19x | CN¥-45.33 Million |
| 2023 | 9.30% | 22.53% | 0.35x | 1.19x | CN¥-12.31 Million |
| 2024 | 7.65% | 18.85% | 0.32x | 1.27x | CN¥-43.03 Million |
| 2025 | 6.96% | 16.09% | 0.35x | 1.22x | CN¥-59.92 Million |
Industry Comparison
This section compares R&G PharmaStudies Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,971,753,361
- Average return on equity (ROE) among peers: 9.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| R&G PharmaStudies Co. Ltd. A (301333) | CN¥2.00 Billion | 34.76% | 0.20x | $816.88 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $15.70 Million | 0.00% | 0.12x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $137.64 Million | 1.69% | 8.09x | $1.37 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $387.30 Million | 7.50% | 0.60x | $384.41 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $156.83 Million | 24.69% | 0.38x | $473.06 Million |
| Chengzhi Shareholding Co Ltd (000990) | $663.54 Million | 6.09% | 0.18x | $1.28 Billion |
| Hualan Biological EngineeringInc (002007) | $13.85 Billion | 7.86% | 0.18x | $3.36 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $256.72 Million | 9.82% | 0.22x | $1.10 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $763.33 Million | 17.77% | 0.08x | $4.78 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $469.29 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.45 Billion | 14.73% | 0.06x | $1.63 Billion |
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology se… Read more